Graves' Orbitopathy (Thyroid Eye Disease) Support Protocol
Primary Stack
Core supplements with strongest evidenceAntioxidant; reduces orbital inflammation; improves quality of life in mild GO
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsImmune modulation; deficiency associated with autoimmune thyroid disease
Supporting Studies (1)
Anti-inflammatory; may support ocular surface health
Supporting Studies (1)
Reduces oxidative stress in orbital tissues
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Graves' Orbitopathy (GO), also called Thyroid Eye Disease (TED), is an autoimmune condition affecting the muscles and tissues around the eyes. It usually occurs with Graves' disease (hyperthyroidism) but can occur before or after thyroid problems.
SYMPTOMS:
DISEASE PHASES:
RISK FACTORS:
CRITICAL: GO requires ophthalmological management. This protocol is SUPPORTIVE ONLY.
MEDICAL TREATMENTS:
MOST IMPORTANT:
* Selenium has strong evidence for mild GO (EUGOGO trial).
* Vitamin D supports immune modulation.
* Antioxidants may help reduce oxidative stress.
Expected timeline: Active phase typically lasts 12-24 months. Selenium shown to improve quality of life within 6 months in mild disease.
Clinical Perspective
Graves' Orbitopathy: Autoimmune inflammation of orbital tissues; shares TSH receptor antigen with thyroid. Severity classification: mild, moderate-to-severe, sight-threatening. Clinical Activity Score (CAS) guides treatment (>3/7 = active). Risk factors: smoking (3-8x risk), RAI therapy, poor thyroid control.
CRITICAL: Selenium has Level 1 evidence for mild GO (EUGOGO RCT). Smoking cessation essential. Maintain euthyroidism. Moderate-to-severe active: IV methylprednisolone, consider teprotumumab (anti-IGF1R). Sight-threatening: urgent IV steroids, decompression. Surgery for inactive disease. Supplements supportive only - selenium is exception with strong evidence in mild disease.
* Selenium (A-grade): Antioxidant. EUGOGO RCT: (PMID: 21508145). 200mcg daily for mild GO.
* Vitamin D (C-grade): Immune modulation. Systematic review: (PMID: 28750270). 2000-4000 IU daily.
* Omega-3 (C-grade): Anti-inflammatory. Review: (PMID: 27840029). 2-3g EPA+DHA daily.
* Antioxidants (C-grade): Oxidative stress. Review: (PMID: 23075608). Vitamin C 500mg, E 400 IU daily.
Assessment targets: Clinical Activity Score, proptosis (Hertel), eyelid measurements, diplopia assessment, visual acuity, optic nerve function.
Protocol notes: Selenium: EUGOGO trial showed benefit in mild GO; 200mcg selenomethionine for 6 months. Smoking: 3-8x increased risk; cessation improves all outcomes. Euthyroid maintenance: both hyper and hypothyroidism worsen GO. RAI: may worsen GO; consider steroid prophylaxis in at-risk patients. Teprotumumab: FDA-approved IGF-1R inhibitor; effective for active moderate-to-severe. IV steroids: methylprednisolone 500mg weekly x 6 weeks, then 250mg x 6 weeks (EUGOGO protocol). Orbital radiotherapy: adjunct to steroids in some cases. Dry eye: aggressive lubrication; may need punctal plugs. Sleep: elevate head; tape lids if exposure. Sunglasses: photosensitivity common; protective. Surgery timing: wait for inactive phase (6+ months stable) except for sight-threatening.